Pathogen Inactivation Technologies for Cellular Blood Components: an Update

Publisher： Karger

E-ISSN： 1660-3818|41|4|309-325

ISSN： 1660-3796

Source： Transfusion Medicine and Hemotherapy, Vol.41, Iss.4, 2014-07, pp. : 309-325

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pathogen Inactivation of Cellular Blood Products – Still Plenty of Reason to Be Careful

By  

Transfusion Medicine and Hemotherapy, Vol. 32, Iss. 5, 2005-09 ,pp. : 258-260

Karger

Access to resources Recommend Favorite

Pathogen Inactivation of Cellular Blood Products – More Security for the Patient or Less?

By  

Transfusion Medicine and Hemotherapy, Vol. 30, Iss. 6, 2003-12 ,pp. : 261-263

Karger

Access to resources Recommend Favorite

Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTM

By  

Transfusion Medicine and Hemotherapy, Vol. 38, Iss. 1, 2011-01 ,pp. : 19-31

Karger

Access to resources Recommend Favorite

Concerning Caspari et al: Pathogen Inactivation of Cellular Blood Products – More Security for the Patient or Less? Transfus Med Hemother 2003;30:261–263

By  

Transfusion Medicine and Hemotherapy, Vol. 32, Iss. 1, 2005-01 ,pp. : 45-48

Karger

Access to resources Recommend Favorite

Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates

By  

Transfusion Medicine and Hemotherapy, Vol. 38, Iss. 1, 2011-01 ,pp. : 33-42

Karger

Access to resources Recommend Favorite